课题基金 / 基金详情

Identification of Inhibitors of human Lactate Dehydrogenase A (LDHA) as Anti-cancer Agents

Identification of Inhibitors of human Lactate Dehydrogenase A (LDHA) as Anti-cancer Agents
人乳酸脱氢酶 A (LDHA) 抑制剂作为抗癌药物的鉴定
批准号:
9205757
负责人:
David Maloney
金额:
$11.4万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

David Maloney的其他基金

相似基金

相关文献

中文摘要
翻译
项目亮点:筛选了完整的化合物库,并确定了一个先导化学型用于开发。药物化学正在改善LDHA抑制活性,并且正在进行一系列先进的分析来表征这些化合物的细胞活性,并支持主要候选药物的临床前进展。
英文摘要
Project highlights: the full compound library was screened and a lead chemotype was identified for development. Medicinal chemistry is ongoing to improve LDHA inhibitory activity, and a battery of advanced assays are in progress to characterize cellular activity of these compounds and support preclinical advancement of a lead candidate. During this period, the NCGC has fostered and maintained over 180 active collaborations with both NIH and extramural investigators, facilitating drug discovery efforts across the entire spectrum of human disease. These efforts have led to over 100 high-throughput screens and nearly 60 medicinal chemistry campaigns, providing our collaborators and the general research community a wealth of publications and promising small molecule leads. In addition, the NCGC has undertaken a number of informatic challenges to make better use of existing drug and disease target information and provide the general public with easily accessible resources, further catalyzing the development of new therapies for human disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ML199: Inhibitor of Ape1 as a Lead for Cancer Therapeutics
Inhibitors of p53-S100B interaction for melanoma
Implications of 12-Lipoxygenase and NOX-1 in beta-Cell dysfunction, a potential target for Diabetes
Discovery of Inhibitors of Human 5-Lipoxygenase and CYP51 as Anti-Fungal Leads
海外基金